• Cambodia
  • India
  • Kazakhstan
  • Kenya
  • Malaysia
  • Moldova
  • Myanmar
  • Philippines
  • Tajikistan
  • Ukraine
  • Uzbekistan
  • Vietnam
banner image

RAVSID TABLETS

  • Product-img

RAVSID TABLETS

More Information

  • Category
    Gastrointestinal Drugs
  • MANUFACTURED BY
    Kusum Healthcare Pvt Ltd.

For Patient

Why you have been prescribed this medicine?

active substance: Rabeprazole sodium; 1 tablet contains 20 mg of rabeprazole sodium; excipients: Mannitol, Light Magnesium Oxide, Cross Povione, Sodium Hydoxide, Colloidal Anhydrous Silica, Crospovidone, Talc, Magnesium Stearate.

When you should consult your doctor?

What to do if you miss a dose?

Things you MUST NOT DO while on this medicine?

What to do if you accidentally take too much (overdose) of the medicine?

Is it safe in pregnancy and breast-feeding?

Tell your doctor immediately if you become pregnant while taking this medication.
For safety of any drug during pregnancy or breastfeeding – please consult your doctor.

Storage Conditions?

For Professionals

Drug Description

Indications and dosage.

INDICATIONS:


Active duodenal ulcer Active benign gastric ulcer Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD). Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance) Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD) Zollinger-Ellison Syndrome. In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease.

DOSAGE:


Adults/older people:Active Duodenal Ulcer and Active Benign Gastric Ulcer: The recommended oral dose for both active duodenal ulcer and active benign gastric ulcer is 20mg to be taken once daily in the morning. Most patients with active duodenal ulcer heal within four weeks. However a few patients may require an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcer heal within six weeks. However again a few patients may require an additional six weeks of therapy to achieve healing. Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20mg to be taken once daily for four to eight weeks. Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of RAVSID 20 mg or 10 mg once daily can be used depending upon patient response. Symptomatic treatment of moderate to very severe gastro-Esophageal reflux disease (symptomatic GERD): 10mg once daily in patients without esophagitis. If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10mg once daily when needed. Zollinger-Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated. Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended. RAVSID 20mg twice daily + clarithromycin 500mg twice daily and amoxicillin 1g twice daily. For indications requiring once daily treatment RAVSID tablets should be taken in the morning, before eating; and although neither the time of day nor food intake was shown to have any effect on rabeprazole sodium activity, this regimen will facilitate treatment compliance. Patients should be cautioned that the RAVSID tablets should not be chewed or crushed, but should be swallowed whole. Renal and hepatic impairment: No dosage adjustment is necessary for patients with renal or hepatic impairment.

Children:


RAVSID is not recommended for use in children, as there is no experience of its use in this group.

Side effects and drug interactions.

The most commonly reported adverse drug reactions, during controlled clinical trials with rabeprazole were headache, diarrhoea, abdominal pain, asthenia, flatulence, rash and dry mouth. The majority of adverse events experienced during clinical studies were mild or moderate in severity, and transient in nature. The following adverse events have been reported from clinical trial and post-marketing experience. Frequencies are defined as: common (> 1/100, < 1/10), uncommon (> 1/1,000, < 1/100), rare (>1/10,000, <1/1000) very rare (<1/10,000), not known (cannot be estimated from the available data).
1 Includes facial swelling, hypotension and dyspnoea

2 Erythema, bullous reactions and hypersensitivity reactions have usually resolved after discontinuation of therapy.
3 Rare reports of hepatic encephalopathy have been received in patients with underlying cirrhosis. In treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with RAVSID is first initiated in such patients (see section
4.4). 4 See Special warnings and precautions for use.

Drug interactions:


Rabeprazole sodium produces a profound and long lasting inhibition of gastric acid secretion. An interaction with compounds whose absorption is pH dependent may occur. Co-administration of rabeprazole sodium with ketoconazole or itraconazole may result in a significant decrease in antifungal plasma levels. Therefore individual patients may need to be monitored to determine if a dosage adjustment is necessary when ketoconazole or itraconazole are taken concomitantly with RAVSID. In clinical trials, antacids were used concomitantly with the administration of RAVSID and, in a specific drug-drug interaction study, no interaction with liquid antacids was observed. Co-administration of atazanavir 300 mg/ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg once daily) to healthy volunteers resulted in a substantial reduction in atazanavir exposure. The absorption of atazanavir is pH dependent. Although not studied, similar results are expected with other proton pump inhibitors. Therefore PPIs, including rabeprazole, should not be co-administered with atazanavir (see Section 4.4). Methotrexate Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted.

Administration during pregnancy or breast-feeding.


Pregnancy: There are no data on the safety of rabeprazole in human pregnancy. Reproduction studies performed in rats and rabbits have revealed no evidence of impaired fertility or harm to the foetus due to rabeprazole sodium, although low foeto-placental transfer occurs in rats. RAVSID is contraindicated during pregnancy. Breast-feeding: It is not known whether rabeprazole sodium is excreted in human breast milk. No studies in breast-feeding women have been performed. Rabeprazole sodium is however excreted in rat mammary secretions. Therefore RAVSID should not be used during breast-feeding.

Children:


RAVSID is not recommended for use in children, as there is no experience of its use in this group.

Overdose:


Experience to date with deliberate or accidental overdose is limited. The maximum established exposure has not exceeded 60mg twice daily, or 160mg once daily. Effects are generally minimal, representative of the known adverse event profile and reversible without further medical intervention. No specific antidote is known. Rabeprazole sodium is extensively protein bound and is, therefore, not dialysable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised. Ability to influence reaction velocity while driving or operating any other mechanisms. Based on the pharmacodynamic properties and the adverse events profile, it is unlikely that RAVSID would cause an impairment of driving performance or compromise the ability to use machinery. If however, alertness is impaired due to somnolence, it is recommended that driving and operating complex machinery be avoided.

Warnings and precautions.